Eagle Bay Advisors’s Pfizer PFE Stock Holding History

Eagle Bay Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,172	Closed	-$364K	–	772
2021 Q4	$364K	Buy	+6,172	New	+$306K	0.23%	68

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TIM

Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Eagle Bay Advisors's PFE Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Pfizer (PFE) in Q1 2025, closing a stake of 6,603 shares — an estimated $175K sold.

Eagle Bay Advisors first reported a position in PFE in Q2 2021 and held it in 15 quarters. The position peaked at $643K in Q2 2022. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

Eagle Bay Advisors reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 6,603 Pfizer shares in Q1 2025, an estimated $175K.
Eagle Bay Advisors first reported a position in Pfizer in Q2 2021 and held it in 15 quarters.
Eagle Bay Advisors's Pfizer position peaked at $643K in Q2 2022.
2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.